Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis
References (12)
- et al.
A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis
Eur J Clin Pharmacol
(1976) Long term oral acetylcysteine in chronic bronchitis. A double-blind controlled study
Eur J Respir Dis
(1980)- et al.
Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report on trial organized by the Swedish Society of Pulmonary Disease
Eur J Respir Dis
(1983) Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction
Thorax
(1985)- et al.
Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis
Eur Respir J
(1988) Mucolytic treatment in chronic obstructive pulmonary disease. Double-blind comparative clinical trials with N-acetylcysteine, bromhexine and placebo
Acta Tuberculosea et Pneumologica Belgica
(1979)
Cited by (80)
The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review
2017, Heart and Lung: Journal of Acute and Critical CareCitation Excerpt :However, here, we found that both high-dose and low-dose NAC reduced the proportion of patients with at least one exacerbation. This difference may be due to the inclusion of additional articles6,7 in the present analysis. The other meta-analysis8 analyzed only the frequency of COPD exacerbation as the endpoint.
Preventing Hospitalizations From Acute Exacerbations of Chronic Obstructive Pulmonary Disease
2017, American Journal of the Medical SciencesPrevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline
2015, ChestCitation Excerpt :The incidence of adverse effects attributed to the study drug did not differ between the NAC and placebo groups. When examined together, the combined data from these studies240–242 demonstrate a reduction in the rate of exacerbations in COPD associated with the use of NAC compared with placebo (OR, 0.61; 95% CI, 0.37-0.99). Although conclusions are limited by the sample size of the studies assessed, oral NAC is well tolerated and appears to represent a low risk to patients.
Treatment of non-cystic fibrosis bronchiectasis
2011, Archivos de BronconeumologiaCitation Excerpt :In general, self-administered techniques are recommended for better compliance. The effectiveness of mucolytics has not been clearly demonstrated in patients with bronchiectasis105 or in patients with other pulmonary pathologies.106–108 The Cochrane systematic review,105 based on the paper by Olivieri et al.,109 suggests that bromhexine is the only mucolytic agent that has demonstrated a certain benefit in the treatment of exacerbations of patients with bronchiectasis.
Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases
2023, AntioxidantsFactorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD): a randomized, double-blind, placebo-controlled trial
2022, European Review for Medical and Pharmacological Sciences